Literature DB >> 19201868

Ignition of p53 bomb sensitizes tumor cells to granzyme K-mediated cytolysis.

Guoqiang Hua1, Shuo Wang, Chao Zhong, Peng Xue, Zusen Fan.   

Abstract

Inactivation of tumor suppressor p53 results in loss of the apoptosis-regulating function of the p53 protein in tumor cells. Restoration of wild-type p53 expression in p53 mutant tumor cells increases tumor susceptibility to CTL-mediated cytolysis. However, the direct role of p53 in regulating tumor sensitivity to NK cell-mediated lysis and the functional relationship between p53 and granzymes in the control of tumor killing are still poorly documented. In this study, we found that p53 can sensitize tumor-killing susceptibility to NK and granzyme K-mediated cytolysis. Granzyme K is constitutively expressed in high levels in NK cells and induces rapid caspase-independent cell death. Granzyme K may exert a critical role in NK cell-mediated tumor clearance. p53 associates with granzyme K and is a physiological substrate of granzyme K. p53 was processed to three cleavage products of p40, p35, and p13 fragments at Lys(24) and Lys(305). These three cleavage products harbor strong proapoptotic activities that amplify the proapoptotic action of p53 to potentiate tumor-killing sensitivity. Therefore, p53 is as a cytotoxic bomb that can be triggered by granzyme K, leading to potentiating killing efficacy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19201868     DOI: 10.4049/jimmunol.0802307

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

Review 1.  Granzyme A activates another way to die.

Authors:  Judy Lieberman
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

Review 2.  A quarter century of granzymes.

Authors:  C L Ewen; K P Kane; R C Bleackley
Journal:  Cell Death Differ       Date:  2011-11-04       Impact factor: 15.828

3.  Granzyme K-deficient mice show no evidence of impaired antiviral immunity.

Authors:  Lars T Joeckel; Cody C Allison; Marc Pellegrini; Catherina H Bird; Phillip I Bird
Journal:  Immunol Cell Biol       Date:  2017-04-21       Impact factor: 5.126

4.  Granzyme K inhibits replication of influenza virus through cleaving the nuclear transport complex importin α1/β dimer of infected host cells.

Authors:  C Zhong; C Li; X Wang; T Toyoda; G Gao; Z Fan
Journal:  Cell Death Differ       Date:  2011-12-02       Impact factor: 15.828

5.  Mouse granzyme K has pro-inflammatory potential.

Authors:  L T Joeckel; R Wallich; P Martin; D Sanchez-Martinez; F C Weber; S F Martin; C Borner; J Pardo; C Froelich; M M Simon
Journal:  Cell Death Differ       Date:  2011-02-11       Impact factor: 15.828

6.  Granzyme K synergistically potentiates LPS-induced cytokine responses in human monocytes.

Authors:  Annette C Wensink; Vera Kemp; Job Fermie; M Isabel García Laorden; Tom van der Poll; C Erik Hack; Niels Bovenschen
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-07       Impact factor: 11.205

7.  FADD cleavage by NK cell granzyme M enhances its self-association to facilitate procaspase-8 recruitment for auto-processing leading to caspase cascade.

Authors:  S Wang; P Xia; L Shi; Z Fan
Journal:  Cell Death Differ       Date:  2011-10-07       Impact factor: 15.828

8.  hSMG-1 is a granzyme B-associated stress-responsive protein kinase.

Authors:  Franck Meslin; Ahmed Hamaï; Bernhard Mlecnik; Filippo Rosselli; Catherine Richon; Abdelali Jalil; Gregory Wemhoff; Jerome Thiery; Jerome Galon; Salem Chouaib
Journal:  J Mol Med (Berl)       Date:  2011-02-08       Impact factor: 4.599

9.  All human granzymes target hnRNP K that is essential for tumor cell viability.

Authors:  Robert van Domselaar; Razi Quadir; Astrid M van der Made; Roel Broekhuizen; Niels Bovenschen
Journal:  J Biol Chem       Date:  2012-05-11       Impact factor: 5.157

10.  Human NK cell lytic granules and regulation of their exocytosis.

Authors:  Konrad Krzewski; John E Coligan
Journal:  Front Immunol       Date:  2012-11-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.